Navigation Links
Diopsys, Inc. Launches New Website for Doctors and Patients, www.Diopsys.com
Date:5/12/2011

PINE BROOK, N.J., May 12, 2011 /PRNewswire/ -- Diopsys, Inc. launched its new website – www.diopsys.com - that showcases the company's growing product line and vision for the future. The new website features expanded product information, educational resources for physicians and patients, as well as improved navigation and search capabilities. The re-designed site was initiated to address the growing need of customers and patients to have access to the most up-to-date clinical information.

The site's new homepage has a clean, clear design that enables visitors to quickly find the section of the site that most applies to them. The "News and Events" section gives visitors a quick look at what is going on with Diopsys' core technology, Visual Evoked Potential (VEP), the meetings Diopsys is attending, and current vision testing news. "We wanted to create a more accessible, user-friendly site for customers and patients to find the information they were looking for quickly, but also introduce them to additional knowledge on our vision testing technology," says Caitlin Ryan-Wise, Marketing Manager for Diopsys.

One of the most clinically beneficial sections of Diopsys.com is the "Case Studies" section.  Optometrists, Ophthalmologists and Pediatricians each have their own area to review patient case studies that their peers have contributed.  This gives physicians a chance to communicate with one another on how they are using Diopsys VEP vision testing systems to enhance their patient care.

"Additionally," Ryan-Wise says, "with the most recent launch of the Diopsys® NOVA-DN VEP Vision Testing System for optic nerve disorders including glaucoma, we have had a significant increase in optometrists and ophthalmologists looking for information on our products.  We felt now was a great time to re-vamp the site for prospective customers and investors."

Diopsys, Inc. (http://www.diopsys.com) is a medical instrumentation company dedicated to delivering high-quality, cost-effective preventative health care.  The company specializes in the development and marketing of patient-friendly, non-invasive diagnostic vision testing equipment.  Diopsys has developed and markets the patented Enfant® Pediatric Vision Testing System, a device used by pediatricians to test for visual deficits, including amblyopia, in children as young as six months of age. Diopsys also developed and markets the Diopsys® NOVA-DT (Diagnostic & Tracking), Diopsys® NOVA-TR (Transient Response) and Diopsys® NOVA-DN (Diseases of the Optic Nerve)  Vision Testing Systems utilized by ophthalmologists and optometrists for the detection, diagnosis and treatment of vision disorders.


'/>"/>
SOURCE Diopsys, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Cobalis Corp. Launches National Television Commercials for PreHistin® Allergy Defense Formula
2. Pierrel Research USA Launches Orabloc™ a New Purer Articaine
3. Life Technologies Launches 7500 Fast Dx Real-Time PCR Instrument and 3500 Dx Series Genetic Analyzer in Japan
4. BD Launches BD MAX™ Open System in Europe and Reveals Strategy to Build Broad Menu of Assays that Provide Timely, Accurate Information to Laboratories and Clinicians
5. Quest Diagnostics Launches Simplexa™ C. Difficile Universal Direct Test in Europe
6. Bacterin International Holdings Launches Third Biologic Scaffold
7. Millennium Laboratories Launches New Educational Webinar Series for Pain Management Physicians
8. Remedi SeniorCare® Launches Electronic Order Entry Capability as Part of the My Remedi® Suite of Online Tools
9. Nonin Medical Launches Low Power Xpod®, Model 3012LP, OEM Pulse Oximeter Globally
10. Netsmart Technologies Launches Exchange for Customers to Share Applications and Information
11. Watson Launches Generic Concerta®
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/9/2016)... Mitsubishi Tanabe Pharma Corporation (Head Office: ... Dr. Masayuki Mitsuka ) has presented data that ... intravenously in 10-14 day cycles for 48 weeks experienced ... Functional Rating Scale-Revised (ALSFRS-R). The data were presented at ... Dublin, Ireland . In ...
(Date:12/9/2016)... , Dec 9, 2016 Research and Markets ... 2016-2020" report to their offering. ... The global travel vaccines market to grow ... The report covers the present scenario and the growth prospects of ... size, the report considers the revenue generated from the sales of ...
(Date:12/9/2016)...  Forge Therapeutics, Inc. today announced a strategic ... TecDAX, ISIN: DE0005664809) to advance its novel Gram-negative ... bacterial infections including those caused by drug resistant ... antibacterial target for more than the past 15 ... points has hampered its progress. Forge has been ...
Breaking Medicine Technology:
(Date:12/9/2016)... ... ... "I have gout, and I wanted to treat it naturally," said an ... relieve gout and pain caused by varicose veins. I drank it every morning for ... what VA doctors called the worst sinusitis case they'd seen and relieved gas, stress ...
(Date:12/9/2016)... ... December 09, 2016 , ... Sober College, the ... the grand opening of the Sober College Robert Pfeifer Memorial Learning Center at ... 2-3, and was attended by an overwhelming amount of alumni, family, colleagues and ...
(Date:12/9/2016)... ... December 09, 2016 , ... Mediaplanet today announces distribution of the latest edition ... to sign up as an organ donor for the 123,000 people in the United ... donor can save up to 8 saves through organ donation and enhance many others ...
(Date:12/9/2016)... (PRWEB) , ... December 09, 2016 , ... ... whiteboard display solutions, proudly announced today that a new solution for Emergency Departments ... fit in the tight space in Emergency Department examination rooms, and with a ...
(Date:12/9/2016)... ... December 09, 2016 , ... The ... Cable Network (PCN) during the summer of 2016. The program was made possible ... the United States Department of Health and Human Services Administration. The broadcast, ...
Breaking Medicine News(10 mins):